- Moderna Inc MRNA and Gavi, the Vaccine Alliance, agreed to cancel the remaining pending orders under the current COVID-19 vaccine supply agreement for 2022 based on the original coronavirus strain.
- Instead, Moderna will supply up to 100 million doses of its new, variant-adapted vaccines at its lowest price from 2023.
- Moderna's agreement with Gavi has led to the supply of nearly 70 million doses of COVID-19 vaccines to the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries, in addition to the company facilitating the donation of more than 100 million doses to these countries.
- Related: US Health Official Says Updated COVID-19 Boosters Should Offer Protection Amid Tracking Emerging Variants.
- GAVI chief executive Seth Berkley said the new agreement was a "critical step for equitable access" to allow lower-income countries to use the modified vaccines as they see fit.
- Many wealthier countries have started using the vaccine in booster campaigns.
- Price Action: MRNA shares are up 4.44% at $139.95 on the last check Monday.
Loading...
Loading...
MRNAModerna Inc
$25.70-0.77%
Edge Rankings
Momentum
5.54
Growth
Not Available
Quality
Not Available
Value
70.11
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in